Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | ENO1 | P06733 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002275 | 0.77 | KMT2A (0.50) | MEN1TSHRKMT2ATDP1 | |
| SCHEMBL6011904 | 0.77 | MAPT (0.40) | LMNATSHRKMT2ATDP1 | |
| SCHEMBL8583505 | 0.76 | KMT2A (0.54) | MEN1TSHRKMT2ATDP1 | |
| SCHEMBL8584405 | 0.76 | KMT2A (0.54) | MEN1TSHRKMT2ATDP1 | |
| SCHEMBL7741804 | 0.76 | KMT2A (0.54) | MEN1TSHRKMT2ATDP1 | |
| SCHEMBL10709425 | 0.76 | KMT2A (0.54) | MEN1TSHRKMT2ATDP1 | |
| SCHEMBL8414887 | 0.76 | KMT2A (0.54) | MEN1TSHRKMT2ATDP1 | |
| SCHEMBL28684308 | 0.75 | MAPT (0.44) | LMNATSHRKMT2ATDP1 | |
| SCHEMBL28696440 | 0.75 | MAPT (0.44) | LMNATSHRKMT2ATDP1 | |
| SCHEMBL28696059 | 0.75 | MAPT (0.44) | LMNATSHRKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| EP-1556347-A4 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2006-08-09 | — | — | EP | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
| EP-1556347-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-27 | — | — | EP | disclosed |
| WO-2003103604-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V (AN) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | MEN1 3591/4885LMNA 1060/4885HPGD 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.